Last reviewed · How we verify

NCT03787433: ARCANGEL

Assisted Rehabilitation Care During Post-stroke mANaGement: fEasibiLity Assessment

Completed Last updated 16 June 2020
What this trial tests

trial testing ARC - Assisted Rehabilitation Care in Stroke in 41 participants. Completed in 12 June 2020.

Timeline
23 November 2018
Primary endpoint
12 June 2020
12 June 2020

Quick facts

Lead sponsorCamlin Ltd
StatusCompleted
Study typeOBSERVATIONAL
Enrollment41
Start date23 November 2018
Primary completion12 June 2020
Estimated completion12 June 2020
Sites2 locations across Italy, United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Camlin Ltd

Who can join

18 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The ARCANGEL study evaluates the feasibility of introducing ARC (Assisted Rehabilitation Care), a new device for home-based post-stroke rehabilitation in the current clinical practise. All the stroke survivors included in the study will received their own equipment to be used at home for 6 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. An early feasibility study for neurological devices: The ARCTRAN study.
    Bove F, Di Lazzaro G, Petracca M, Lo Monaco MR, et al · · 2025 · cited 1× · PMID 40679690 · DOI 10.1007/s10072-025-08367-5

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Camlin Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03787433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing